Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Bad financial results growth rate -8.1% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (6.7%)
  • Dividend yield for the last twelve months 3.9%
  • Free cash flow yield -0.2% (LTM)
  • Share price is 14.0% higher than minimum and 37.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-0.5%)83.79
year average price 92.01  


year start price 118.59 2024-09-05

max close price 118.64 2024-09-18

min close price 73.47 2025-05-14

current price 84.18 2025-09-04
Common stocks: 2 528 810 012

Dividend Yield:  3.9%
FCF Yield LTM: -0.2%
EV / LTM EBITDA: 10.0x
EV / EBITDA annualized: 9.8x
Last revenue growth (y/y):  -1.9%
Last growth of EBITDA (y/y):  -14.3%
Historical revenue growth:  +3.9%
Historical growth of EBITDA:  +9.5%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 211 889
Net Debt ($m): 26 847
EV (Enterprise Value): 238 736
EBITDA LTM ($m): 23 763
EV / LTM EBITDA: 10.0x
Price to Book: 4.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-03businesswire.com

Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

2025-09-03zacks.com

MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline

2025-09-02businesswire.com

Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

2025-08-30businesswire.com

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

2025-08-28zacks.com

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

2025-08-28zacks.com

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

2025-08-28businesswire.com

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

2025-08-25businesswire.com

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

2025-08-19zacks.com

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

2025-08-19zacks.com

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data